The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

A competitive drug market strongly encourages companies to best their rivals by developing the next generation of life-saving therapies.

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. President Trump said he has decided on who he plans to nominate to replace ...

The Zepbound price cut is the latest move in a price war with Denmark’s Novo Nordisk, which is making it significantly less ...